Literature DB >> 2454893

Immunization with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine: effect of a booster dose on antibody levels in humans.

S J Cryz1, J C Sadoff, E Fürer.   

Abstract

Healthy adult volunteers were vaccinated on day 0 and 28 and at 15 months with a Pseudomonas aeruginosa immunotype 5 O polysaccharide-toxin A conjugate vaccine. Immunization resulted in mild, transient local reactions in less than 20% of the subjects. Maximal immunoglobulin G (IgG) antibody titers to both toxin A and lipopolysaccharide (LPS) as determined by enzyme-linked immunosorbent assay were seen at day 42, at which time 50% of the vaccinees showed a fourfold or greater rise in toxin A-neutralizing titers. By 15 months postvaccination, both antitoxin A and anti-LPS IgG antibodies had markedly declined. A booster dose of vaccine administered at 15 months evoked a vigorous anti-toxin A IgG antibody response with 100% of the volunteers showing a fourfold or greater rise in neutralizing antibody titer compared with preimmunization levels. In contrast, there was no significant elevation of anti-LPS IgG antibody levels. At 24 months postimmunization, only anti-toxin A antibody levels were significantly higher than preimmunization levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454893      PMCID: PMC259485          DOI: 10.1128/iai.56.7.1829-1830.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; E Furer; J C Sadoff; R Germanier
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

2.  Immunization against Pseudomonas in infection after thermal injury.

Authors:  J Wesley; A Fisher; M W Fisher
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

3.  Protective activity of an intravenous immune globulin (human) enriched in antibody against lipopolysaccharide antigens of Pseudomonas aeruginosa.

Authors:  M S Collins; R E Roby
Journal:  Am J Med       Date:  1984-03-30       Impact factor: 4.965

4.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

5.  Safety and immunogenicity of Haemophilus influenzae type B polysaccharide-diphtheria toxoid conjugate vaccine in adults.

Authors:  M L Lepow; J S Samuelson; L K Gordon
Journal:  J Infect Dis       Date:  1984-09       Impact factor: 5.226

6.  Carrier-induced epitopic suppression, a major issue for future synthetic vaccines.

Authors:  M P Schutze; C Leclerc; M Jolivet; F Audibert; L Chedid
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

7.  Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients.

Authors:  R J Jones; E A Roe; J L Gupta
Journal:  Lancet       Date:  1980-12-13       Impact factor: 79.321

Review 8.  Infections caused by Pseudomonas aeruginosa.

Authors:  G P Bodey; R Bolivar; V Fainstein; L Jadeja
Journal:  Rev Infect Dis       Date:  1983 Mar-Apr

9.  Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans.

Authors:  A S Cross; J C Sadoff; B H Iglewski; P A Sokol
Journal:  J Infect Dis       Date:  1980-10       Impact factor: 5.226

10.  A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; E Fürer; J C Sadoff; R Germanier
Journal:  Antibiot Chemother (1971)       Date:  1987
View more
  8 in total

Review 1.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

2.  Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers.

Authors:  D Cohen; S Ashkenazi; M Green; Y Lerman; R Slepon; G Robin; N Orr; D N Taylor; J C Sadoff; C Chu; J Shiloach; R Schneerson; J B Robbins
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

3.  Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.

Authors:  L C Paoletti; M A Rench; D L Kasper; D Molrine; D Ambrosino; C J Baker
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

4.  Synthesis of Oligosaccharide Components of the Outer Core Domain of P. aeruginosa Lipopolysaccharide Using a Multifunctional Hydroquinone-Derived Reducing-End Capping Group.

Authors:  Abhishek Vartak; Fatma M Hefny; Steven J Sucheck
Journal:  Org Lett       Date:  2017-12-29       Impact factor: 6.005

5.  Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.

Authors:  R K Gupta; W Egan; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

6.  Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A.

Authors:  A Fattom; R Schneerson; D C Watson; W W Karakawa; D Fitzgerald; I Pastan; X Li; J Shiloach; D A Bryla; J B Robbins
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.609

Review 7.  Pseudomonas aeruginosa: Recent Advances in Vaccine Development.

Authors:  Matthew Killough; Aoife Maria Rodgers; Rebecca Jo Ingram
Journal:  Vaccines (Basel)       Date:  2022-07-08

8.  Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate.

Authors:  A Fattom; J Shiloach; D Bryla; D Fitzgerald; I Pastan; W W Karakawa; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.609

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.